Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer

In our phase Ib trial (ClinialTrials.gov Identifier: NCT03855358), benmelstobart (TQB2450), a novel humanized IgG1 antibody against PD-L1, plus antiangiogenic multikinase inhibitor, anlotinib, demonstrated promising antitumor activities in pretreated triple negative breast cancer (TNBC) patients. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yiqun, Wang, Jiayu, Sun, Tao, Ouyang, Quchang, Li, Jianwen, Yuan, Jie, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654734/
https://www.ncbi.nlm.nih.gov/pubmed/37973901
http://dx.doi.org/10.1038/s41392-023-01672-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654734/
https://www.ncbi.nlm.nih.gov/pubmed/37973901
http://dx.doi.org/10.1038/s41392-023-01672-5

Ejemplares similares